John Denning, DO
Family Medicine · San Diego, CANPI 1508818246
Payments from drug & device makers
Across 65 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$338
- Merck$225
- Alnylam Pharmaceuticals Inc.$146
- Sanofi-aventis U.S. LLC$105
- Bayer$104
- E.r. Squibb & Sons, L.L.C.$97
- plus $808 from 19 others
What the payments were for
- Food & beverage$1,824100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $338 |
| Merck | 7 | $225 |
| Alnylam Pharmaceuticals Inc. | 1 | $146 |
| Sanofi-aventis U.S. LLC | 5 | $105 |
| Bayer | 1 | $104 |
| E.r. Squibb & Sons, L.L.C. | 1 | $97 |
| Novo Nordisk | 6 | $97 |
| AstraZeneca | 5 | $84 |
| Exact Sciences | 5 | $79 |
| Pfizer | 3 | $69 |
| Lilly USA, LLC | 3 | $68 |
| Amgen | 3 | $60 |
| Johnson & Johnson | 1 | $55 |
| Sanofi Pasteur Inc. | 2 | $53 |
| Inspire Medical Systems, Inc. | 2 | $46 |
| Kaleo, Inc. | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Gilead | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Phadia US Inc. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$146
- SHINGRIX$122
- AREXVY$120
- PNEUMOVAX 23$119
- Kerendia$104
How this compares
$1,824 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 67 | $490 |
| Allopurinol | 26 | $266 |
| Losartan Potassium | 21 | $216 |
| Rosuvastatin Calcium | 18 | $210 |
| Lisinopril | 35 | $143 |
| Omeprazole | 21 | $105 |
| Levothyroxine Sodium | 16 | $99 |
| Hydrochlorothiazide | 20 | $71 |
| Amlodipine Besylate | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Other family medicine in San Diego
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Laurie Han-ConradSan Diego$2.9M
- Sheldon MorrisSan Diego$1.1M
- Mirwais SaifiSan Diego$1M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.